Profile: Acura Pharmaceuticals Inc (ACUR.OQ)
17 Apr 2014
Acura Pharmaceuticals, Inc. incorporated on April 10, 1935, is a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse, utilizing its Aversion and Impede Technologies. Aversion is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules designed to address some common methods of product tampering associated with abuse. Impede Technology is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. As of December 31. 2012, the Company had seven additional opioid products utilizing Aversion in various stages of development.
The Company’s product, Oxecta is a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. Oxecta utilizes its Aversion Technology. The Company’s Aversion Technology Opioid products in development include Hydrocodone bitartrate/acetaminophen, Hydromorphone HCl, Methadone HCl, Morphine Sulfate, Oxycodone HCl/acetaminophen, Oxymorphone HCl and Tramadol HCl. On January 23, 2012, Oxecta was made commercially available by Pfizer Inc. (Pfizer).
The Company’s Nexafed product is an immediate-release pseudoephedrine HCl, tablet which utilizes its Impede Technology. Pseudoephedrine HCl (PSE) is a nasal decongestant available in many non-prescription and prescription cold, sinus and allergy products. The Company conducts research, development, laboratory, manufacturing, and warehousing activities at its operations facility in Culver, Indiana and lease an administrative office in Palatine, Illinois.
Acura Pharmaceuticals Inc
Suite 120, 616 N. North Court
PALATINE IL 60067